Washington, D.C. 20549


CURRENT REPORT Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 1, 2019

(Exact name of registrant as specified in its charter)


(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

Block 10-1
Blanchardstown Corporate Park, Ballycoolin
Dublin 15, Ireland
(Address of Principal Executive Offices)
Not Applicable
(Zip Code)

Registrant’s telephone number, including area code: +353 1 485 1200


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting  standards provided pursuant to Section 13(a) of the Exchange Act.  
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Ticker symbol(s)
Name of each exchange on
which registered
American Depositary Shares*
NASDAQ Stock Market LLC
Ordinary Shares**
(NASDAQ Global Market)

American Depositary Shares may be evidenced by American Depository Receipts. Each American Depositary Share represents one (1) Ordinary Share.
Nominal value $0.01 per share. Not for trading, but only in connection with the listing of American Depositary Shares.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 1, 2019, Kevin Kotler notified the Board of Directors of Avadel Pharmaceuticals plc (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.  Mr. Kotler’s decision to resign as a director was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On October 4, 2019, the Company issued a press release announcing Mr. Kotler’s resignation from the Company’s Board of Directors, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Press release dated October 4, 2019, issued by Avadel Pharmaceuticals plc

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary
Date: October 4, 2019
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2020 to May 2020 Click Here for more Avadel Pharmaceuticals Charts.
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2019 to May 2020 Click Here for more Avadel Pharmaceuticals Charts.